Overview

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

Status:
RECRUITING

Trial end date:
2026-02-25

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the bioequivalence of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (100 mg, test product) and Abraxane (100 mg, reference product) in breast cancer patients.

Phase:

PHASE1

Details

Lead Sponsor:

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel